Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYXQBF)

Drug Name

CEP-37251 Drug Info

Synonyms

ART-010; EGX-010; OVP (bone loss), Peptech; Osteoprotegerin variant protein (bone loss), Arana; Osteoprotegerin variant protein (bone loss), EvoGenix; Osteoprotegerin variant protein (bone loss), Peptech

Indication

Disease Entry	ICD 11	Status	REF
Bone metastases	2D50	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DMYXQBF

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Osteoclast differentiation factor (ODF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Denosumab	DMNI0KO	Drug-induced osteoporosis		Approved	[3]
ALX-0141	DMBGI74	Osteoporosis	FB83.0	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Osteoclast differentiation factor (ODF)	TT9E8HR	TNF11_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01159873) Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women. U.S. National Institutes of Health.
2	This week in therapeutics Cancer. SciBX 3(40); doi:10.1038/scibx.2010.1202. Oct. 14, 2010
3	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
4	Clinical pipeline report, company report or official report of Ablynx.